Theramir’s proprietary technologies are based on microRNAs (miRNAs), a class of small non-coding RNAs that can regulate multiple genes and pathways associated with cancer growth and metastasis. The company has developed a panel of miRNAs, both biological and synthetic, which can affect the function and disrupt expression of an expanding list of oncoproteins that are dysregulated in most cancer types. Thus, our technologies can be applied to the development of novel targeted therapeutics that may potentially transform the precision oncology field by creating new knowledge on the pathology of the disease and by enabling the customization and personalization of cancer treatment.